Glenview Trust Co boosted its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 2.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 376,892 shares of the company’s stock after acquiring an additional 9,616 shares during the period. Glenview Trust Co’s holdings in Merck & Co., Inc. were worth $45,336,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in shares of Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after purchasing an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after buying an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC raised its stake in shares of Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after buying an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC lifted its holdings in Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after buying an additional 6,897 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after buying an additional 359,356 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
MRK has been the subject of a number of analyst reports. Scotiabank lifted their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a report on Tuesday, June 30th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Guggenheim raised their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Finally, Morgan Stanley lifted their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.94.
Merck & Co., Inc. Stock Down 2.4%
Merck & Co., Inc. stock opened at $124.41 on Tuesday. The company’s 50 day simple moving average is $120.37 and its 200 day simple moving average is $117.14. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $131.74. The firm has a market capitalization of $307.27 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 5.04 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current year.
Merck & Co., Inc. Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were issued a dividend of $0.85 per share. The ex-dividend date was Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.7%. Merck & Co., Inc.’s payout ratio is currently 95.77%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Read More
- Five stocks we like better than Merck & Co., Inc.
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
